Navigation Links
New guideline from ASH and ASCO recommends caution regarding ESA use in cancer patients
Date:10/26/2010

(WASHINGTON, October 25, 2010) An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia. While the guideline cautions that ESAs are associated with shorter survival and increased risk of thromboembolism blood clots and tumor progression, it also recognizes their major benefit of reducing the need for red blood cell transfusions, which can potentially cause serious infections and adverse reactions in the immune system.

"This updated guideline offers clinicians the latest synthesis of the medical evidence surrounding use of ESAs in patients with cancer, including appropriate cautions where evidence is lacking or where risks may outweigh the use of ESAs," said J. Douglas Rizzo, MD, MS, Co-Chair of the guideline panel and Professor of Medicine at the Medical College of Wisconsin.

Those risks may include thromboembolism or even death, according to new data cited in the guideline, which suggests that physicians avoid the use of ESAs in cancer patients who are not receiving chemotherapy, except for those with myelodysplastic syndrome (MDS). At the same time, the guideline confirms the effectiveness of ESAs in sparing patients the need for transfusions, which can substantially impact quality of life. By recommending that physicians discuss individual risks and benefits of ESAs and blood transfusion with patients prior to therapy, the guideline recognizes the critical role of shared decision-making between the patient and the physician.

In addition to outlining the clotting risks of ESAs, the guideline makes specific recommendations on usage and provides insights into disease progression and patient survival. The guideline also details new thresholds for initiation and modification of ESAs, which are consistent with current FDA labeling.

Originally published in 2002 and last updated in 2007, the guideline was derived from analysis of individual patient data, various medical literature, and systematic reviews of published clinical trials. In developing the update, panel members considered all relevant literature published between January 2007 and January 2010. Additional evidence was considered when it was considered pertinent to each section of the updated guideline.

"These guidelines touch on almost all aspects of the use of ESAs in patients with cancer and MDS, as well as secondary issues, such as the role of iron supplementation," said Samuel Silver, MD, a member of ASH's Committee on Practice and Professor of Internal Medicine at the University of Michigan. "These are issues that confront practicing hematologists and oncologists on a daily basis, and we hope that these evidence-based recommendations will influence practice standards and result in better care for patients."


'/>"/>

Contact: Lindsey Love
llove@hematology.org
202-552-4925
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Experts unveil new CVD guidelines and position papers at Canadian Cardiovascular Congress 2010
2. Pediatricians Issue New Iron Guidelines
3. UH Case Medical Center receives Get With The Guidelines Gold Plus Performance Achievement Award
4. New CPR Guidelines Emphasize Compressions First
5. Most Doctors Dont Follow Colon Cancer Screening Guidelines
6. OCTANE study influences revision of WHO guidelines for treating some HIV-infected women
7. Not all doctors follow cancer screening guidelines
8. New osteoporosis guidelines: Osteoporosis Canada
9. Mammogram Guidelines Still Beget Confusion
10. New Medicare model guidelines for benefit years 2012-2014 in development
11. Leading practitioners recommend global PTSD treatment guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... help improve all aspects of people’s health and nutrition, announced its product Leyzene ... , Natural Subsistence develops nutritional supplements that help people improve all aspects ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! ... thinking about summer internships , which can be frustrating when they don’t even ... Garden Media Group, a boutique public relations firm outside of Philadelphia, have offered these ...
(Date:3/23/2017)... NC (PRWEB) , ... March 23, 2017 , ... Inflow ... ride). Life is serious so build on a solid foundation. As experts in ... priority vital information that is coming soon. Inflownomics deliver ripe, fresh, clean & refreshing ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is now offering ... Verisys through its FACIS and other services maintains the largest healthcare ... “We are delighted to be able to offer these various products to our ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality ... 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. ... not only to the association, but also to the Health Care Quality and Patient ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... LUND, Sweden , Mar 23, 2017 ... mitochondrial medicine company, today announced that the English version of ... company,s website www.neurovive.com .  ... About NeuroVive NeuroVive Pharmaceutical ... committed to the discovery and development of medicines that preserve ...
(Date:3/23/2017)... Sweden , Mar 23, 2017 The ... notice to the Annual General Meeting, which is to take place ... Scheelevägen 2 in Lund, Sweden . ... Please see the attached notification, ... och Inrikes Tidningar. NeuroVive Pharmaceutical AB (Publ) The Board ...
(Date:3/22/2017)... PUNE, India , March 23, 2017 ... 2017 - 2021, a latest research report. The global ... market is shift of surgeons focus toward minimally invasive ... popular or limited to few developed countries having high ... ...
Breaking Medicine Technology: